gene therapy
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
Conditions
Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
Trial Timeline
Oct 22, 2014 → Mar 7, 2022
NCT ID
NCT01395641About gene therapy
gene therapy is a phase 1/2 stage product being developed by PTC Therapeutics for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT01395641. Target conditions include Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01395641 | Phase 1/2 | Completed |
Competing Products
1 competing product in Aromatic L-amino Acid Decarboxylase (AADC) Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AAV2-hAADC | PTC Therapeutics | Phase 2 | 49 |